Radiofrequency ablation

The Inner Circle acknowledges Lars R. Newsome, MD as a Pinnacle Life Member

Retrieved on: 
Wednesday, March 6, 2024

DELMAR, Calif., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lars R. Newsome, MD is acknowledged as a Pinnacle Life Member for his contributions to the fields of Anesthesiology and Interventional Pain Management.

Key Points: 
  • DELMAR, Calif., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lars R. Newsome, MD is acknowledged as a Pinnacle Life Member for his contributions to the fields of Anesthesiology and Interventional Pain Management.
  • The doctor is board certified in anesthesiology, pain management, critical care management, and transesophageal echocardiography.
  • Dr. Newsome is affiliated with the San Diego Spine and Orthopedic Center and works with Dr. Eric S. Korsh.
  • A pain management specialist is a doctor who specializes in pain medicine, focusing on the evaluation, treatment and prevention of pain.

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

Retrieved on: 
Thursday, February 15, 2024

The transaction consists of AngioDynamics’ PICC, Midline and tip location products.

Key Points: 
  • The transaction consists of AngioDynamics’ PICC, Midline and tip location products.
  • This combined portfolio of products contributed approximately $43.5 million in annual sales during AngioDynamics’ fiscal year 2023.
  • These products contributed approximately $5.5 million in annual sales during AngioDynamics’ fiscal year 2023.
  • The divestiture of the PICC and Midline businesses, together with the discontinuance of the radiofrequency ablation and Syntrax businesses, will reduce full-year fiscal 2024 revenue by approximately $50 million.

Dr. Chad Stephens Joins Physician Partners of America in Texas

Retrieved on: 
Thursday, February 8, 2024

FORT WORTH, Texas, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce a partnership with Noble Pain Management and Sports Medicine (Noble Pain and Sports). They are excited to welcome the founder of Noble Pain and Sports, interventional pain management and sports medicine physician, Chad Stephens, DO, to their Fort Worth North practice in Texas. He is now seeing patients at the office, located at 4364 Heritage Trace Pkwy #112B, Fort Worth, TX 76244.

Key Points: 
  • Physician Partners of America acquires Noble Pain Management & Sports Medicine.
  • FORT WORTH, Texas, Feb. 8, 2024 /PRNewswire-PRWeb/ -- Physician Partners of America (PPOA) is pleased to announce a partnership with Noble Pain Management and Sports Medicine (Noble Pain and Sports).
  • They are excited to welcome the founder of Noble Pain and Sports, interventional pain management and sports medicine physician, Chad Stephens, DO, to their Fort Worth North practice in Texas.
  • Joining a group of well-established pain partners, I hope to help lead how quality Interventional Pain Management is provided in Texas."

Attune Medical® Announces Support of AF Symposium 2024

Retrieved on: 
Wednesday, January 17, 2024

Attune Medical®, a pioneer in the field of esophageal temperature management with its ensoETM® device, is providing significant support for the upcoming AF Symposium as part of the company’s corporate mission.

Key Points: 
  • Attune Medical®, a pioneer in the field of esophageal temperature management with its ensoETM® device, is providing significant support for the upcoming AF Symposium as part of the company’s corporate mission.
  • AF Symposium, scheduled for February 1-3 in Boston, Massachusetts, gathers the world's leading electrophysiologists to share, in a highly interactive environment, the latest advances in the treatment of atrial fibrillation.
  • (Photo: Business Wire)
    As part of its mission to support education and enhance patient outcomes, Attune Medical is the primary corporate sponsor of the AF Symposium EP Fellows’ Scholarship Program and the dedicated Interactive Educational Program for fellows on Saturday, February 3 from 4-8 p.m.
  • The AF Symposium Fellows’ Program offers a unique opportunity to engage with leaders in Cardiac Electrophysiology during this exclusive four-hour session.

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Retrieved on: 
Tuesday, January 2, 2024

FDA guidance suggests the goal is to complete 510(k) review within 90 calendar days, not including time required by the Company to respond to additional information requests.

Key Points: 
  • FDA guidance suggests the goal is to complete 510(k) review within 90 calendar days, not including time required by the Company to respond to additional information requests.
  • “In my professional opinion, with FDA and worldwide regulatory clearance, the CellFX nsPFA Cardiac Clamp may become the gold standard in cardiac ablation for cardiothoracic surgeons.
  • We expect the CellFX nsPFA Cardiac Clamp will demonstrate the superior safety and effectiveness of nsPFA for cardiac ablation in cardiac surgery and will serve as an entry point into this large and growing market.
  • Along with our CellFX nsPFA 360 Cardiac Catheter, we plan to surround cardiac care teams with next generation nsPFA technology to drive better patient outcomes,” said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences.

Aerin Medical Announces Sustained Clinical and Quality-of-Life Improvements Two Years After Chronic Rhinitis Treatment with RhinAer®

Retrieved on: 
Tuesday, December 5, 2023

RELIEF demonstrated that a single procedure with RhinAer®, a temperature-controlled, radiofrequency technology, resulted in sustained improvements in chronic rhinitis symptoms, including post-nasal drip and chronic cough, and quality of life through two years along with a substantial decrease in chronic rhinitis medication usage.

Key Points: 
  • RELIEF demonstrated that a single procedure with RhinAer®, a temperature-controlled, radiofrequency technology, resulted in sustained improvements in chronic rhinitis symptoms, including post-nasal drip and chronic cough, and quality of life through two years along with a substantial decrease in chronic rhinitis medication usage.
  • View the full release here: https://www.businesswire.com/news/home/20231205015241/en/
    Two-year results of the RELIEF clinical trial published in The Laryngoscope confirm that a single procedure with RhinAer® resulted in sustained improvements in chronic rhinitis symptoms and quality of life, along with a substantial decrease in chronic rhinitis medication usage.
  • RhinAer, a non-invasive technology developed by Aerin Medical Inc., uses temperature-controlled, radiofrequency energy to provide relief from chronic rhinitis.
  • ENTs use RhinAer as a non-invasive alternative to surgical interventions to directly interrupt nerve signals and help reduce chronic rhinitis symptoms.

Interventional Spine Devices Market to grow by USD 3.07 billion from 2023 to 2028; North America to account for 47% of market growth- Technavio

Retrieved on: 
Monday, November 20, 2023

NEW YORK, Nov. 20, 2023 /PRNewswire/ -- The interventional spine devices market is expected to grow by USD 3.07 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Nov. 20, 2023 /PRNewswire/ -- The interventional spine devices market is expected to grow by USD 3.07 billion from 2023 to 2028.
  • North America is estimated to contribute 47% to the growth of the global market during the forecast period.
  • Detailed information on factors that will drive the growth of the interventional spine devices market between 2023 and 2028.
  • Growth of the interventional spine devices market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of interventional spine device market companies.

Neurent Medical Announces New CPT Code® for Chronic Rhinitis Treatment Offering Significant Symptom Improvements

Retrieved on: 
Monday, November 13, 2023

GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market. The Centers for Medicare and Medicaid Services (CMS) has recently assigned a Category I Current Procedural Terminology (CPT®) reimbursement code for a breakthrough minimally invasive procedure designed to address the symptoms of patients suffering from chronic rhinitis.

Key Points: 
  • GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market.
  • The establishment of this CPT code is a significant milestone for physicians who treat chronic rhinitis patients.
  • The new code describes the procedure performed by otolaryngologists or ear, nose, and throat (ENT) physicians when disrupting overactive nerves that drive chronic rhinitis symptoms.
  • It is estimated that several million chronic rhinitis patients are seen by ENT doctors annually in the United States.

Aerin Medical Announces Advances for Chronic Rhinitis Treatment with New CPT® Code and Final CMS-Established Payment Rates

Retrieved on: 
Friday, November 3, 2023

The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.

Key Points: 
  • The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.
  • View the full release here: https://www.businesswire.com/news/home/20231031993246/en/
    CMS is set to implement a new CPT code that improves access to chronic rhinitis treatment with RhinAer® for patients often stuck in an unproductive cycle of care.
  • RhinAer is supported by a strong body of clinical evidence demonstrating significant, durable symptom improvement for chronic rhinitis patients.
  • Treatment with RhinAer is non-invasive and can be performed by ENT physicians in the office and outpatient surgical settings.

Cardiology Applications Drive Dominance in the Radiofrequency Ablation Devices Market, Fueled by Rising Cardiovascular Disease Prevalence - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023

The increasing prevalence of chronic diseases, especially cardiovascular diseases and cancers, coupled with a growing elderly population and technological innovations in these devices, is fueling the demand for radiofrequency ablation devices.

Key Points: 
  • The increasing prevalence of chronic diseases, especially cardiovascular diseases and cancers, coupled with a growing elderly population and technological innovations in these devices, is fueling the demand for radiofrequency ablation devices.
  • Cardiovascular Diseases: A major cause of global mortality, driving the demand for radiofrequency ablation devices.
  • The escalating incidence of cardiovascular diseases is expected to drive the demand for radiofrequency ablation devices, especially in the treatment of atrial fibrillation.
  • Radiofrequency ablation devices are widely used in oncology and cardiology to treat conditions such as tumors and arrhythmias.